Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.52 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.52 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 3/20 | 0.51 |
| ▸ | BRAF | P15056 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179120 | 0.89 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1SRD5A2IP6K1 | |
| SCHEMBL2744691 | 0.87 | RXRB (0.61) | SRD5A2GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL1809969 | 0.85 | RAF1 (0.53) | SLC1A3SLC1A2SLC1A1RAF1BRAF | |
| SCHEMBL2428750 | 0.84 | CYP2C8 (0.56) | SRD5A2GRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL29771953 | 0.82 | CNR2 (0.58) | SRD5A2IP6K1IP6K3IP6K2ALDH1A1 | |
| SCHEMBL1812217 | 0.82 | AKR1C3 (0.57) | SRD5A2IP6K1IP6K3IP6K2ALDH1A1 | |
| SCHEMBL26375402 | 0.81 | SLC1A3 (0.50) | SLC1A3SLC1A2SLC1A1RAF1BRAF | |
| SCHEMBL29784385 | 0.81 | AKR1C3 (0.62) | SRD5A2IP6K1IP6K3IP6K2ALDH1A1 | |
| SCHEMBL22442328 | 0.81 | AKR1C3 (0.62) | SRD5A2IP6K1IP6K3IP6K2ALDH1A1 | |
| SCHEMBL4192450 | 0.81 | AKR1C3 (0.59) | SLC1A3SLC1A2SLC1A1SRD5A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | claimed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | claimed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | claimed |
| CN-101437800-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC (BM) | 2009-05-20 | — | — | CN | claimed |
| EP-3023097-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150025074-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | BUONAMICI SILVIA (US) | 2015-01-22 | — | — | US | disclosed |
| CN-104224791-A | Methods and compositions for treating solid tumors and other malignancies | NOVARTIS AG | 2014-12-24 | — | — | CN | disclosed |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | DORSCH MARION (US) | 2014-07-17 | — | — | US | disclosed |
| US-8778927-B2 | Smoothened antagonism for the treatment of hedgehog pathway-related disorders | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-8507471-B2 | Biphenylcarboxamide derivatives as hedgehod pathway modulators | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| EP-2617414-A2 | Smoothened antagonism for the treatment of hedgehog pathway-related disorders | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | disclosed |
| WO-2010037715-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2010-04-08 | — | — | WO | disclosed |
| EP-2162190-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-17 | — | — | EP | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| CN-101437800-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC (BM) | 2009-05-20 | — | — | CN | disclosed |
| EP-2021328-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025074-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | MTOR, ULK1, HRAS | SLC1A3 4618/4885SLC1A2 4735/4885SLC1A1 4740/4885 |
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | MCL1, ABL1, BCR | SLC1A3 4339/4885SLC1A2 4576/4885SLC1A1 4387/4885 |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | SLC1A3 2416/4885SLC1A2 2332/4885SLC1A1 2096/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | SLC1A3 3473/4885SLC1A2 2942/4885SLC1A1 3255/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | SLC1A3 3473/4885SLC1A2 2942/4885SLC1A1 3255/4885 |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, SMO | SLC1A3 2079/4885SLC1A2 2501/4885SLC1A1 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.